Larger studies are needed to provide more meaningful results. The present evidence supports the use of cyproterone acetate or spironolactone ideally combined with ethinylestradiol as the best ...
Day One Biopharmaceuticals (DAWN) announced three-year results from the OJEMDA pivotal Phase 2 FIREFLY-1 trial in an oral presentation at the 30th ...
Recent polling shows oncologists changing inclination in treatment for mHSPC based on tolerability profiles.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback